Prosensa awarded $200K research grant Prosensa announced that Judith van Deutekom, Prosensa's vice president of drug discovery, has been awarded a $200K research grant from Parent Project Muscular Dystrophy to fund the development of a multi exon-skipping strategy for exons 10-30 of the dystrophin gene. The project titled "Single AON-induced multiple exon skipping in the mdx mouse model" will focus on obtaining proof-of-concept in the mdx mouse model. The studies are expected to be completed in 2H15.
Prosensa upgraded to Overweight from Underweight at JPMorgan JPMorgan upgraded Prosensa two notches to Overweight citing a favorable risk/reward around the potential approval of Drisapersen for Duchenne muscular dystrophy. The firm believes regulatory risk for the drug has been significantly reduced in both the U.S. and Europe. JPMorgan raised its price target for shares to $18 from $4.40.